Bethesda, MDNCT05996536Now EnrollingIRB Ready

Lipodystrophy Clinical Trial in Bethesda, MD

Access cutting-edge lipodystrophy treatment through this clinical trial at a research site in Bethesda. Study-provided care at no cost to qualified participants.

Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Quick Self-Assessment

See if you qualify for this Bethesda location

Preparing your pre-screening questions…

Expert Care in Bethesda

Access lipodystrophy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related lipodystrophy treatment provided free

Apply for This Bethesda Location

Check if you qualify for this lipodystrophy clinical trial in Bethesda, MD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Bethesda

    Convenient for MD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Bethesda site if eligible
  4. 4Begin participation

About This Lipodystrophy Study in Bethesda

Background: People with familial partial lipodystrophy (FPLD) do not store fat in the body normally. This can lead to serious illnesses such as diabetes and heart disease. To learn more about FPLD, researchers want to compare the fat tissue in people with this disease to the fat tissue of healthy people. Objective: To collect and analyze samples of fat tissue in people with and without FPLD. Eligibility: People aged 18 to 65 years with FPLD. Healthy adults are also needed. Design: Participants will be screened. They will have a physical exam. The size and shape of their body will be measured. They will have an imaging scan to measure their bones, muscle, and fat. Participants will be given heavy water to drink at home. The water contains a tracer to help measure the fat in their blood. They will drink 1 vial 3 times a day. After drinking the water for 9 days, participants will come to the clinic for a 3-day stay. They will eat only foods provided by the hospital; the foods will contain tracers. A needle will be inserted into a vein in the arm; participants will receive infusions of other tracers through this needle into their blood; this needle will also be used to draw blood samples for testing. On their third day in the clinic, participants will have biopsies: Small samples of fat will be removed from under the skin on the belly and thigh. Participants may return for a follow-up visit 8 days after leaving the clinic. Blood draws and fat tissue biopsies will be repeated.

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Who Can Participate

Inclusion Criteria

Common inclusion criteria (FPLD and Controls): In order to be eligible to participate in this study, an individual must meet all of the following criteria:
Stated willingness to comply with all study procedures and availability for the duration of the study
Age \>= 18 and \<= 65 years
Agreement to adhere to Lifestyle Considerations throughout study duration.
Weight stability (per the subject) within approximately 3 kg in the 3 months prior to screening, with no plans to actively gain or lose weight during the study period. FPLD-specific inclusion criteria:
Clinical diagnosis of partial lipodystrophy based on reduction in adipose tissue outside the normal range in selected adipose depots (including, at a minimum, the gluteofemoral depot) with preservation of adipose tissue in other depots.
Adequate abdominal and thigh adipose tissue for feasible subcutaneous fat biopsy, as judged by the investigator. CONTROL MATCHING CRITERIA: When possible, control subjects will be individuals matched 1:1 with the FPLD subjects based on the following criteria (in order of priority). These criteria will be considered when assessing eligibility but are not strict inclusion criteria.
Age plus-minus 5 years
Diabetic status
Abdominal circumference plus-minus 10 cm
Height plus-minus 5 cm

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:
Uncontrolled diabetes, defined as HbA1C \>8% at screening.
Use of insulin secretagogues (sulfonylureas) in week prior to Study Visit 1.
Changes in insulin dose \>30% of total daily dose in the 2 weeks prior to Study Visit 1.
Use of niacin in the week prior to Study Visit 1.
Use of antiplatelets that cannot be safely held for the appropriate duration prior to each biopsy visit, including Plavix (one week prior to biopsy), aspirin (one week prior to biopsy) and NSAIDS (48 hours prior to biopsy).
Chronic use of anticoagulant medications that cannot be safely stopped for an appropriate duration of time prior to a biopsy procedure.
Lipemia defined as non-fasting triglycerides of \>1000 mg/dL at screening.
Renal dysfunction defined as GFR \<60 mL/min/1.73 m\^2 at screening.
Consuming extreme macronutrient diet (e.g., very low-carbohydrate, high fat diets such as ketogenic, paleo or Atkins diets, among others).
Positive pregnancy test or breastfeeding at screening.
History of HIV, hepatitis B or C infection.
History of acquired lipodystrophy.
Clinically significant abnormalities in thyroid function, liver function, blood counts, or blood minerals as assessed by screening labs.
Inability to comply with planned study procedures.
Inability of subject to understand and the willingness to sign a written informed consent document.
Any condition which in the opinion of the investigator increases risk to subjects, prevents subject from complying with study procedures, prevents the subject from completing the study, or interferes with the interpretation of study results.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Bethesda?

Yes, this clinical trial (NCT05996536) has an active research site in Bethesda, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Lipodystrophy Treatment Options in Bethesda, MD

If you're searching for lipodystrophy treatment options in Bethesda, MD, this clinical trial (NCT05996536) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Bethesda research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lipodystrophy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all lipodystrophy clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Hypertension Trials in Bethesda, MD

See all pulmonary hypertension clinical trials recruiting in Bethesda — not just this study.

Browse Pulmonary Hypertension Trials in Bethesda

Ready to Join in Bethesda?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Bethesda, MD